Archive for the ‘oncotarget’ Category
Researchers in China have retracted a 2016 cancer imaging paper because they introduced “a plethora of data errors” while preparing the article for submission.
Although the retraction notice provides no details on what these errors are or how exactly they occurred, it does point the finger at the researchers, explaining that the data errors happened as a result of their “negligence.”
Here’s the 2017 retraction notice for “Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma,” published November 25, 2016 in Oncotarget: Read the rest of this entry »
A federal investigation into a paper on prostate cancer has now led to a retraction. In an unusual twist, it happened following a request from the animal rights group People for the Ethical Treatment of Animals (PETA).
In January, the Office of Research Integrity reported that corresponding author Dong Xiao “intentionally fabricated data” in an Oncotarget study of how a steroid inhibits the growth of prostate cancer. Xiao, a former cancer researcher at the University of Pittsburgh, claimed that he had tumor data from more mice than he did, and falsified several figures.
In July, after no sign of the retraction, a researcher at PETA followed up with the journal, Oncotarget, on behalf of the organization “and our more than 3 million members and supporters to request the immediate retraction.”
Last month, they received a reply from the publisher, which they forwarded to us:
A former researcher at the University of Pittsburgh inflated the number of mice used in his experiments, and faked data in a number of images in a paper reporting the results, according to the Office of Research Integrity (ORI).
Dong Xiao admitting to having
intentionally fabricated data contained in a paper entitled ‘Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate signaling,’ specifically Figure 6G,